Browse the evidence

Retatrutide increased heart rate by up to 6.7 beats/min, which may offset some benefits of weight loss.

Weight loss treatments like retatrutide may have cardiovascular implications that need to be considered.

NN1706 lowers body weight & improves glycemic control in obese rodents and monkeys.

NN1706 may also be beneficial for weight management and glycemic control in animal models of obesity.

Increased heart rate was observed across NN1706 treatment cohorts.

Clinicians should monitor heart rate in patients receiving NN1706 treatment.

Challenges with GLP-1s include side effects, nutritional deficiencies, and low long-term adherence.

Clinicians should be aware of and manage these challenges when prescribing GLP-1s.

In postmenopausal females with type 2 diabetes, an intensive lifestyle intervention decreased estradiol levels by 15% and bioavailable testosterone by 13% at year 1.

Practitioners should consider the hormonal changes in females when implementing weight loss interventions.

Tirzepatide has similar gastrointestinal adverse reactions and contraindications as traditional GLP-1 receptor agonists.

Clinicians should be aware of the potential for similar side effects when prescribing tirzepatide.

The therapeutic efficacy of poly-agonists is likely to change the treatment paradigm for obesity.

Healthcare providers may need to adapt to new treatment protocols involving poly-agonists.

Designer drugs using mono, dual, and triple agonists of GLP-1, GIP, and glucagon can promote weight loss without effort.

Practitioners may consider these drugs as potential options for patients struggling with obesity.

Approximately 50% of diabetes remitters experience relapse at 20 years post-surgery.

Long-term monitoring is essential for patients who achieve remission to manage potential relapse.

Gastrointestinal tract adverse events were reported by 63.4% of participants on semaglutide.

Practitioners should monitor for gastrointestinal side effects in patients taking semaglutide.

GLP-1RA prescriptions significantly increased across all BMI categories among youth and adults with type 1 diabetes over the last 15 years.

Clinicians should consider the increasing use of GLP-1RAs in managing obesity in T1D patients.

Patients who received the fluid-filled IGB were more likely to require urgent evaluation or treatment compared to those treated with the gas-filled IGB.

Clinicians should be aware of the higher likelihood of complications with the fluid-filled IGB.

GLP-1RAs may have little or no effect on breast cancer risk.

Practitioners should consider that GLP-1RAs may not significantly increase breast cancer risk based on current evidence.

The limited efficacy and adverse effects of available oral pharmacotherapies pose a significant obstacle in the fight against obesity.

Practitioners should be aware of the limitations of current oral obesity treatments.

The mechanism-based therapeutic potential and limitations of oral poly-GPCR agonism strategy to augment intestinal GLP-1 for weight loss are projected.

Practitioners should evaluate the potential of oral poly-GPCR agonism in enhancing GLP-1 for weight loss.

The plant-based, low-fat diet resulted in substantially greater glucose and insulin levels.

Practitioners should be aware that a plant-based, low-fat diet may increase glucose and insulin levels.

Retatrutide raises cardiovascular safety concerns due to dose-dependent increases in heart rate and incidents of mild to moderate cardiac arrhythmias.

Clinicians should monitor cardiovascular health in patients using retatrutide.

The review focuses on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the context of anti-obesity drug discovery.

Practitioners should consider the role of GLP-1 RAs in developing new anti-obesity therapies.

Future research is needed to determine the ideal SGLT-2 inhibitor or GLP-1RA for weight loss management and the efficacy of combination therapies.

Practitioners should stay informed about ongoing research for optimal weight loss strategies using these medications.

Tirzepatide is a first in class dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) analog approved for the management of adult patients with type 2 diabetes mellitus.

Tirzepatide can be prescribed to adults with type 2 diabetes as part of their treatment plan.

GIP(1-30)NH2 has similar effects on glucose and bone metabolism in healthy individuals as GIP(1-42).

GIP(1-30)NH2 may be considered a viable alternative to GIP(1-42) for influencing glucose and bone metabolism.

GIP(1-30)NH2 results in similar glucagonotropic and insulinotropic effects as GIP(1-42).

GIP(1-30)NH2 could be used similarly to GIP(1-42) in clinical settings for managing insulin and glucagon levels.

Current anti-obesity medications primarily focus on increasing satiety and reducing appetite.

Practitioners should be aware of the current focus of obesity medications when considering treatment options.

Postoperative weight regain (WR) affects 20-30% of patients after bariatric surgery.

Clinicians should be aware that a significant portion of bariatric surgery patients may experience weight regain.